bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive tests for the detection of early-stage lung cancer and other lung diseases, today ...

SAN ANTONIO, January 13, 2025--(BUSINESS WIRE)--bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive tests for the detection of early ...

SAN ANTONIO - bioAffinity Technologies, Inc. (NASDAQ:BIAF; BIAFW), a company specializing in noninvasive diagnostics for early-stage cancer, has reported a 21% increase in April ...

SAN ANTONIO - bioAffinity Technologies, Inc. (NASDAQ:BIAF; BIAFW), a company specializing in noninvasive early-stage lung cancer diagnostics, announced today the acceptance of its patent ...

Metabolic incorporation of an unnatural amino acid allows researchers to rapidly affinity purify newly synthesized ... of an unnatural amino acid with a bio-orthogonal affinity handle.

bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive tests for the detection of early-stage lung cancer and other lung diseases, today ...

bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive tests for the detection of early-stage cancer and lung disease, today reported the ...

bioAffinity Technologies (BIAF) reported the results of the Company’s CyPath Lung pilot marketing program using Texas for our beta launch with sales of more than 600 tests delivered in 2024 ...